瑞公司在专利到期期间通过收购寻求收入增长. Pfizer seeks revenue growth via acquisitions amid patent expirations.

由于关键药物的专利到期, 瑞面临巨大的收入损失. Pfizer faces significant revenue losses due to patent expirations on key drugs. 为了应对这一问题,该公司进行了战略收购,包括用于癌症治疗的Seagen和针对肥胖药物的Metsera. To counter this, the company made strategic acquisitions including Seagen for cancer treatments and Metsera for obesity drugs. 尽管最近股票表现疲软, 但瑞的利率强和药物候选产品有望恢复长期投资者. Despite weak stock performance recently, Pfizer's strong profit margins and a robust pipeline of drug candidates suggest potential for recovery for long-term investors.